[ad_1]
Wall Street is betting tens of millions of dollars on psychedelic drugs that backers say could treat mental illness for a fraction of what it costs to do therapy with better-known treatments.
Transcend Therapeutics Inc. raised $40 million from venture-capital investors in January to develop a post-traumatic stress disorder treatment that its 29-year-old CEO Blake Mandell says would require about half the amount of therapy as MDMA, or ecstasy, a popular hallucinogen. Gilgamesh Pharmaceuticals Inc. and Lusaris Therapeutics Inc. have announced capital raises of about $100 million since November for similar products addressing depression.
[ad_2]
Source link
24World Media does not take any responsibility of the information you see on this page. The content this page contains is from independent third-party content provider. If you have any concerns regarding the content, please free to write us here: contact@24worldmedia.com
Zosia VanMeter becomes Director of Inspection
Saugus playground gets revamped – Itemlive
Fatal Mattituck fire raises questions about rental safety
Photos: CAST’s 5th Annual Festival of Trees lights up Treiber Farms in Peconic
Daily Update: Fatal Mattituck fire raises questions about rental safety
Lynn football luncheon scores big
Police Logs 11/27/24 – Itemlive
Marblehead strike settled – Itemlive
Four Classical greats honored in City Hall
Swampscott hosts Thanksgiving Hero Meals
Controversial project redesign OK’d in Peabody
LYSOA celebrates its relaunch with a new logo and expanded program